Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis
NCT ID: NCT00479947
Last Updated: 2007-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
100 participants
INTERVENTIONAL
2007-05-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methodology
Study participants
Inclusion criteria:
* Premenopausal women suffering from acute or chronic yeast vaginitis and a past history of 3 or 4 episodes over the 12 months will be selected.
* All participants must be symptomatic, i.e. the participant must have identified herself as suffering from one or more of the following: abnormal/odourless vaginal discharge, dyspareunia or dysuria, localized irritation or discomfort around the vagina.
Exclusion criteria:
* Participants must not be suffering from other urogenital infections or conditions such as HIV that will potentially alter their response to disease. Participants will be tested and excluded for the presence of Trichomonas vaginalis and Bacterial vaginosis at inclusion. Other conditions will be ruled out on the basis of medical history and clinical assessment.
* Participants must not be pregnant.
* Participants must not be younger than 18 or older than 50 years.
* Participants must not be menstruating during diagnosis or treatment
Laboratory Diagnosis:
Microscopic examination of vaginal secretion in 10% KOH for hyphae and mycelia Culture for fungal agent using Sabbraoud agar/broth.
Randomisation:
• Participants randomised for age, history of previous (past year) yeast vaginitis.
Treatment Protocol 100 premenopausal women presenting with acute yeast vaginitis and a past history of 3 or 4 episodes of yeast vaginitis over the past 12 months will be treated with one oral dose of Fluconazole (Diflucan), then randomized into 2 groups:
* Group A: Receiving one oral dose of Fluconazole + oral placebo capsules for 3 months.
* Group B: Receiving one oral dose of Fluconazole + capsules of L. rhamnosus GR-1 and L reuteri RC-14 containing 5 billion live organisms for 3 months.
Both groups of patients will be followed at 7days for proof of cure, 1 month, 2 months and 3 months following enrolment.
At all follow-up visits, the patients will be checked for symptoms and examined physically. Vaginal swabs will be tested for fungi microscopically and by culture, and BV organisms using Nugent scoring or with BV Blue test kit for vaginal sialidase.
Data to be collected
Symptoms:
* Lifestyle questionnaire, to include daily self-assessment of presence and severity of condition (discharge, irritation,) for the first 7 days. To include self-determined definition of when recovery begins and when it is complete. Also include menstrual cycle information (during the treatment, is the subject in early, mid or late cycle?).
* Physician assessment at each visit.
Vaginal swabs - two per visit:
* Day 0 (before treatment)
* Day 7 (Proof of cure for the two groups).
* 1 month after treatment
* 2 months after treatment
* 3 months after treatment.
Statistical Analysis
In the placebo group of patients, it is anticipated that at the 3 month period, a recurrence rate of 50% will occur, whereas, in the treatment arm a reduction in recurrence to 25% will be achieved. The study is designed to have a power of 80% and to detect a reduction in recurrence at two-sided 5% significance level.
Participants Recruitment:
Subjects will be recruited from the women attending urogenital tract infection clinics at Faith Mediplex, Benin City.
Risk No risks are expected except the usual adverse effects associated with Fluconazole, otherwise probiotic lactobacilli are generally regarded as safe (GRAS) and no known side effects have been attributed to probiotic lactobacilli in immunocompetent individuals.
Benefits There may be benefits accruing from the probiotic arm of the study as recurrence rate may be low than the placebo. Also there may not be any direct benefit, but information gathered will help us in evaluating whether oral use of probiotics could be practically applicable in our environment against vaginal yeast infections.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotics (Natural product)
Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All participants must be symptomatic, i.e. the participant must have identified herself as suffering from one or more of the following: abnormal/odourless vaginal discharge, dyspareunia or dysuria, localized irritation or discomfort around the vagina.
Exclusion Criteria
* Participants must not be pregnant.
* Participants must not be younger than 18 or older than 50 years.
* Participants must not be menstruating during diagnosis or treatment
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Faith Mediplex
OTHER
UrexBiotech
UNKNOWN
Chr Hansen
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chinonye C EZE-OKOROIKPA, MBBS
Role: STUDY_CHAIR
Faith Mediplex
MARTIN U DURU, MSc
Role: STUDY_DIRECTOR
Faith Mediplex
KINGSLEY C ANUKAM, PhD
Role: PRINCIPAL_INVESTIGATOR
Benson Idahosa University, Benin City and Canadian R & D Centre for Probiotics, Lawson Health Research Intsitute, London, Ontario, Canada. [email protected]
ALFRED AIYEBELEHIN, MBBS
Role: STUDY_CHAIR
Faith Mediplex
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
FaithMediplex
Benin City, Edo, Nigeria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J Antimicrob Chemother. 2006 Aug;58(2):266-72. doi: 10.1093/jac/dkl246. Epub 2006 Jun 21.
Osset J, Garcia E, Bartolome RM, Andreu A. [Role of Lactobacillus as protector against vaginal candidiasis]. Med Clin (Barc). 2001 Sep 22;117(8):285-8. doi: 10.1016/s0025-7753(01)72089-1. Spanish.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UB-CHr-N
Identifier Type: -
Identifier Source: org_study_id